The deal also now includes exclusive rights for China's largest vaccine company to explore a collaboration on GSK's (GSK.L), opens new tab respiratory syncytial virus (RSV) vaccine, Arexvy ...

The deal also now includes exclusive rights for China's largest vaccine company to explore a collaboration on GSK's respiratory syncytial virus (RSV) vaccine, Arexvy, in China, the world's No.2 ...

Under the revised agreement, GSK will collaborate exclusively with Zhifei on the commercialization of its respiratory syncytial virus vaccine Arexvy in China for an initial period of 10 years ...

GSK said Zhifei also has agreed to exclusively engage in discussions of a potential collaboration on the commercialisation of its respiratory syncytial virus vaccine, Arexvy, subject to regulatory ...

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

There was a slightly worse-than-expected performance for respiratory syncytial virus (RSV) vaccine Arexvy and a decline in sales for GSK's important vaccines business. While outside the usual RSV ...

GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes When GSK penned the Zhifei pact last year, the companies said there’s a possibility to potentially expand the ...